Physician profile
Chippy C Ajithan
NPI 1598741795
$3,481.23
in general payments reported to CMS, 2019-2025
27 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $251 · 2021: $583 · 2022: $585 · 2023: $462 · 2024: $583 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $710.64 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $429.07 | 2021-2024 | Verquvo |
| Pfizer INC. | $373.23 | 2019-2024 | |
| Amgen INC. | $344.36 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $236.87 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $234.25 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $206.01 | 2019-2022 | |
| Madrigal Pharmaceuticals | $127.12 | 2025 | Rezdiffra |
| Lexicon Pharmaceuticals, INC. | $122.05 | 2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.42 | 2019-2023 | Jardiance |
| Kestra Medical Technology Services, INC. | $88.17 | 2022-2023 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $72.10 | 2019-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $52.83 | 2020-2022 | |
| Boston Scientific Corporation | $43.97 | 2021-2022 | |
| Acutus Medical, INC. | $40.07 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39.24 | 2023 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $35.26 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $29.33 | 2023 | Arcalyst |
| Philips North America LLC | $27.50 | 2025 | Diagnostic Ecg Service |
| Medtronic, INC. | $24.84 | 2023 | Linq II |
| Cvrx, INC. | $24.69 | 2024 | Barostim Neo System |
| Astellas Pharma US INC | $22.94 | 2023 | Veozah |
| Abbott Laboratories | $21.81 | 2019 | |
| Esperion Therapeutics, INC. | $18.74 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.40 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.34 | 2019 | |
| Sobi, INC | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chippy Ajithan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.